We therefore tested the hypothesis that treatment with galantamine, which is a cholinesterase inhibitor with FDA approval for the treatment of AD (Lilienfeld, 2002; Hampel et al., 2018; Haake et al., 2020), would recover the AIE-induced cholinergic pathology in the adult basal forebrain. This evidence concerns the gene BCHE and Alzheimer disease.